ArticleJournal of veterinary internal medicine2026
Effectiveness and long-term safety of repeated oral administrations of molidustat in the management of anemia associated with chronic kidney disease in cats.
Article in Journal of veterinary internal medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundErythropoietic effects of molidustat, a hypoxia-inducible factor-prolyl hydroxylase inhibitor, occur in anemic cats with chronic kidney disease (CKD). HYPOTHESIS/
objectivesTo evaluate the effectiveness and safety of molidustat in managing anemia in cats with CKD. ANIMALS: Seventy-five client-owned anemic cats with CKD in the effectiveness and safety phase and 64 in the safety continuation phase.
methodsMulticenter, randomized, double-masked, placebo-controlled field study. Cats in the 28-day effectiveness and safety phase received 5 mg/kg of molidustat (n = 40) or a control product (CP; n = 35), once daily for 28 days. During the 20-week safety continuation phase, all cats received 5 mg/kg molidustat in 28-day treatment cycles once PCV declined to < 28%. Individual cat treatment success, defined as a ≥ 4% point increase in hematocrit (HCT) compared to baseline, was evaluated on day 28. Safety was assessed throughout both phases.
resultsProportion of molidustat-treated cats with treatment success on day 28 (68% ± 7.4%; 95% CI, 51.45-80.28) was significantly higher compared to CP cats (17% ± 6.4%; 95% CI, 7.80-33.59; P < .001). During the safety continuation phase, median treatment cycle duration was 28 days with treatment intermission medians ranging from 11 to 18 days. There was no evidence of adverse effects attributed to molidustat when administered alone or in combination with other medications. CONCLUSIONS AND CLINICAL IMPORTANCE: Molidustat significantly increased HCT values in treated cats compared to CP cats. Repeated 28-day treatment cycles were well-tolerated. Molidustat is an effective and safe treatment for long-term management of anemia in cats with CKD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.